Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer

Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.


Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer

Kazia has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for the use of paxalisib in the treatment of atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly aggressive childhood brain cancer.


Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children. 


V-Con: Small Cap Showcase - Kazia Interview and Presentation